Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS)

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 2, 2016, Pages 190-195

  Davies, Rebecca ^a   Carrasco, Roberto ^a   Foster, Helen E ^b   Baildam, Eileen M ^c   Chieng, S E Alice ^d   Davidson, Joyce E ^e   Ioannou, Yiannis ^f   Wedderburn, Lucy R ^f,g   Thomson, Wendy ^a,h   Hyrich, Kimme L ^a,h  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^d ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^e ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Biologic therapy; DMARD therapy; Juvenile idiopathic arthritis; Treatment

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CANAKINUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; ANTIRHEUMATIC AGENT;

ARTHRITIS; ARTICLE; CHILD; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG EFFICACY; ENTHESITIS; FEMALE; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; POLYARTHRITIS; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SCHOOL CHILD; UNITED KINGDOM; ADOLESCENT; ARTHRITIS, JUVENILE; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; PRACTICE PATTERNS, PHYSICIANS'; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84992049029     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.06.001     Document Type: Article

References (16)

1. [1] Gewanter, H.L., Roghmann, K.J., Baum, J., The prevalence of juvenile arthritis. Arthritis Rheum 26 (1983), 599–603.
2. [2] Petty, R.E., Southwood, T.R., Manners, P., Baum, J., Glass, D.N., Goldenberg, J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31 (2004), 390–392.
3. [3] Dueckers, G., Guellac, N., Arbogast, M., Dannecker, G., Foeldvari, I., Frosch, M., et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142 (2012), 176–193.
4. [4] BSPAR. Standards of care for children and young people with juvenile idiopathic arthritis. Available from: 〈https://www.bspar.org.uk/DocStore/FileLibrary/PDFs/BSPAR%20Standards%20of%20Care%20for%20Juvenile%20Idiopathic%20Arthritis.pdf〉 2009 [cited 2009].
5. [5] Prince, F.H., Twilt, M., ten Cate, R., van Rossum, M.A., Armbrust, W., Hoppenreijs, E.P., et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 68 (2009), 635–641.
6. [6] Papsdorf, V., Horneff, G., Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology 50 (2011), 214–221.
7. [7] Horneff, G., Burgos-Vargas, R., Constantin, T., Foeldvari, I., Vojinovic, J., Chasnyk, V.G., et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 73 (2014), 1114–1122.
8. [8] Smith, E.M., Foster, H.E., Beresford, M.W., The development and assessment of biological treatments for children. Br J Clin Pharmacol 79 (2014), 379–394.
9. [9] Stoll, M.L., Cron, R.Q., Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J, 12, 2014, 13.
10. [10] Guzman, J., Oen, K., Tucker, L.B., Huber, A.M., Shiff, N., Boire, G., et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 74 (2014), 1854–1860.
11. [11] McErlane, F., Foster, H.E., Davies, R., Lunt, M., Watson, K.D., Symmons, D.P., et al. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 52 (2013), 1905–1913.
12. [12] Giannini, E.H., Ruperto, N., Ravelli, A., Lovell, D.J., Felson, D.T., Martini, A., Preliminary definition of improvement in juvenile arthritis. Arthr Rheum 40 (1997), 1202–1209.
13. [13] Cordero-Coma, M., Sobrin, L., Anti-tumor necrosis factor-alpha therapy in uveitis. Surv Ophthalmol 60 (2015), 575–589.
14. [14] Sen, E.S., Ramanan, A.V., New age of biological therapies in paediatric rheumatology. Arch Dis Child 99 (2014), 679–685.
15. [15] Davies, R., Kearsley-Fleet, L., Baildam, E., Beresford, M.W., Foster, H.E., Southwood, T.R., et al. Factors associated with choice of first biologic among children with juvenile idiopathic arthritis: a combined analysis from 2 UK paediatric biologic registers. Arthritis Rheumatol 66 (2014), S114–S115.
16. [16] Schmeling, H., Foeldvari, I., Horneff, G., A39: efficacy and safety of methotrexate in oligoarticular persistent juvenile idiopathic arthritis. Arthritis Rheumatol, 66(Suppl. 11), 2014, S59.